Health Sectors Under Pressure: Drug Launch Delays, Merger Moves, and Regulatory Challenges | Health

Drugmakers are postponing new medicine launches in Europe due to US pricing policy pressure under President Trump's administration. Negotiations between pharmaceutical companies and regulators remain ongoing as firms weigh compliance costs against market expansion. The delays signal growing tension between drug pricing reform demands and global market access strategies.